This innovative initiative aims to develop bi-specific antibodies capable of revolutionizing immunological therapies in cancer treatment, particularly focusing on patients who do not respond to curren...
Read moreGonzález's team is working to develop new drugs, based on the inhibition of the RANKL protein, against triple-negative breast cancer
Read moreThese testicular lymphomas, which mainly affected older men, primarily develop in the testis, an immune-privileged site, in other words a place that for physiological reasons is less subject to immune...
Read moreEl Hospital público 12 de Octubre de la Comunidad de Madrid es el primer centro español y uno de los dos europeos en incorporarse a un ensayo clínico internacional, el estudio 'Gliofocus', para com...
Read moreEl VHIO ha participado en dos estudios que podrían suponer una nueva oportunidad terapéutica en el campo de la oncología de precisión para pacientes con cáncer colorrectal metastático con determ...
Read moreResearchers at IDIBAPS- Hospital Clínic have developed and validated a new CAR-T therapy called ARI0003 at a preclinical level. The new therapy combines two therapeutic targets to boost effectiveness...
Read moreLa acumulación de defectos en los procesos de reparación de tejidos a lo largo de nuestra vida se debe tanto a factores genéticos como ambientales. Los científicos piden investigar este posible o...
Read moreThe aim is to penetrate the desmoplastic stroma, the layer surrounding these cancers that acts as a barrier against chemotherapy. Successfully crossing this matrix to reach the tumour directly is vita...
Read moreA multicenter collaboration leaded by the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Germans Trias i Pujol Research Institute (IGTP) identified ...
Read moreAn international scientific team, led by the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), has designed a chemical compound called MACTIDE-V, capable of reprogramming the activity of thes...
Read moreFunding drives the expansion of Quibim’s product pipeline and foundational AI models and accelerates global commercial growth.
Read moreUn estudio del CBM y la UCM muestra que estos tumores reprograman a los monocitos, un tipo de glóbulo blanco protector, para transformarlos en macrófagos que no solo no atacan al cáncer sino que su...
Read more